BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
· BerGenBio to focus on two key opportunities for its lead compound bemcentinib · Strategic focus anchored in strong scientific rationale, supported by dataset from over 600 patients demonstrating bemcentinib’s biological and clinical activity matched with significant unmet medical needs Bergen, Norway, 4 May 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces today an update on its business strategy. BerGenBio will now focus on two key indications; 1st line non-small cell